伴心透管边缘到边缘修复:MiCLASP研究的一年结果
Philipp Lurz1, Thomas Schmitz2, Tobias Geisler3
1Department of Cardiology, University Medical Center Mainz, Mainz, Germany.
JACC. Cardiovascular interventions
|April 10, 2024
概括
在现实环境中,使用PASCAL系统进行中枢管过导管边缘到边缘修复 (M-TEER) 显示出强大的1年安全性和有效性. 这种治疗显著减少了额头骨反,并改善了患者的生存率和生活质量.
科学领域:
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
- 医疗器械 医疗器械
背景情况:
- 额頭管穿透管边缘到边缘修复 (M-TEER) 是严重的症状性额头管吐 (MR) 的推治疗方法.
- 对于PASCAL系统市场后的现实世界结果没有得到广泛的记录.
研究的目的:
- 评估PASCAL系统对M-TEER的30天和1年的安全性和有效性.
- 在欧洲市场后研究中评估临床,心声回声,功能和生活质量结果.
主要方法:
- 预期招募544名患有症状,临床显著MR的患者.
- 主要安全终点:30天复合重大不良事件发生率.
- 主要有效性终点:在出院时的MR严重程度与基线相比,通过心声回声学评估.
主要成果:
- 30天主要不良事件发生率为6.8%.
- 一年后,98%的患者MR≤2+,82.6%的患者MR≤1+.
- 生存率为87.3%,无心力衰竭住院率为84.3%,在1年内.
结论:
- 迈克拉斯普研究证实了M-TEER与PASCAL系统在市场后环境中的安全性和有效性.
- 帕斯卡系统证明了高生存率,心力衰竭住院减少,改善了患者的功能能力和生活质量.
相关概念视频
Mitral Valve Prolapse I: Introduction
IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...
Mitral Valve Prolapse II: Assessment and Management
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular tachycardia.
Mitral Regurgitation III: Medical Management
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
Mitral Stenosis I: Introduction
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Mitral Stenosis II: Clinical features and Diagnostic Tests
Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...


